Suppr超能文献

高密度脂蛋白受体 SR-BI 的外腔半胱氨酸 Cys384 对于其对小分子抑制剂的敏感性和正常脂质转运活性至关重要。

Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity.

机构信息

Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

出版信息

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12243-8. doi: 10.1073/pnas.1109078108. Epub 2011 Jul 11.

Abstract

The HDL receptor, scavenger receptor, class B, type I (SR-BI), is a homooligomeric cell surface glycoprotein that controls HDL structure and metabolism by mediating the cellular selective uptake of lipids, mainly cholesteryl esters, from HDL. The mechanism underlying SR-BI-mediated lipid transfer, which differs from classic receptor-mediated endocytosis, involves a two-step process (binding followed by lipid transport) that is poorly understood. Our previous structure/activity analysis of the small-molecule inhibitor blocker of lipid transport 1 (BLT-1), which potently (IC(50) ∼ 50 nM) blocks SR-BI-mediated lipid transport, established that the sulfur in BLT-1's thiosemicarbazone moiety was essential for activity. Here we show that BLT-1 is an irreversible inhibitor of SR-BI, raising the possibility that cysteine(s) in SR-BI interact with BLT-1. Mass spectrometric analysis of purified SR-BI showed two of its six exoplasmic cysteines have free thiol groups (Cys251 and Cys384). Converting Cys384 (but not Cys251) to serine resulted in complete BLT-1 insensitivity, establishing that the unique molecular target of BLT-1 inhibition of cellular SR-BI dependent lipid transport is SR-BI itself. The C384S substitution reduced the receptor's intrinsic lipid uptake activity by approximately 60% without dramatically altering its surface expression, homooligomerization, or HDL binding. Thus, a small-molecule screening approach identified a key residue in SR-BI involved in lipid transport, providing a powerful springboard into the analyses of the structure and mechanism of SR-BI, and highlighting the power of this approach for such analyses.

摘要

高密度脂蛋白受体、清道夫受体 B 型、I 类(SR-BI)是一种同源寡聚体细胞表面糖蛋白,通过介导细胞对脂质(主要是胆固醇酯)的选择性摄取,控制高密度脂蛋白的结构和代谢。SR-BI 介导的脂质转运的机制不同于经典的受体介导的内吞作用,涉及一个两步过程(结合后脂质转运),目前了解甚少。我们之前对小分子抑制剂脂质转运阻断剂 1(BLT-1)的结构/活性分析表明,该抑制剂能够强有力地(IC50∼50 nM)阻断 SR-BI 介导的脂质转运,其噻唑烷酮部分的硫原子对于活性是必需的。本文中我们表明 BLT-1 是 SR-BI 的不可逆抑制剂,这提示 SR-BI 中的半胱氨酸可能与 BLT-1 相互作用。对纯化的 SR-BI 的质谱分析显示其 6 个细胞外半胱氨酸中有 2 个具有游离巯基(Cys251 和 Cys384)。将 Cys384(但不是 Cys251)突变为丝氨酸导致 BLT-1 完全不敏感,从而确定 BLT-1 抑制细胞 SR-BI 依赖的脂质转运的独特分子靶标是 SR-BI 本身。C384S 取代使受体的内在脂质摄取活性降低了约 60%,而没有显著改变其表面表达、同源寡聚化或与高密度脂蛋白的结合。因此,小分子筛选方法鉴定了 SR-BI 中参与脂质转运的关键残基,为分析 SR-BI 的结构和机制提供了有力的跳板,并突出了这种方法在这种分析中的强大作用。

相似文献

引用本文的文献

2
Nanodiscoidal Nucleic Acids for Gene Regulation.纳米盘状核酸用于基因调控。
ACS Chem Biol. 2023 Nov 17;18(11):2349-2367. doi: 10.1021/acschembio.3c00038. Epub 2023 Nov 1.

本文引用的文献

3
Genetic variant of the scavenger receptor BI in humans.人类清道夫受体 BI 的遗传变异。
N Engl J Med. 2011 Jan 13;364(2):136-45. doi: 10.1056/NEJMoa0907687.
8
The LDL receptor.低密度脂蛋白受体
Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):431-8. doi: 10.1161/ATVBAHA.108.179564.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验